V

VistaGen Therapeutics Inc
NASDAQ:VTGN

Watchlist Manager
VistaGen Therapeutics Inc
NASDAQ:VTGN
Watchlist
Price: 2.49 USD -0.4%
Market Cap: 69.3m USD
Have any thoughts about
VistaGen Therapeutics Inc?
Write Note

Net Margin
VistaGen Therapeutics Inc

-4 518.1%
Current
4 354%
Average
-7.6%
Industry

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
-4 518.1%
=
Net Income
-39.6m
/
Revenue
875.7k

Net Margin Across Competitors

Country US
Market Cap 67.6m USD
Net Margin
-4 518%
Country FR
Market Cap 6T USD
Net Margin
-21 040%
Country US
Market Cap 310.2B USD
Net Margin
9%
Country US
Market Cap 142B USD
Net Margin
13%
Country US
Market Cap 115B USD
Net Margin
0%
Country US
Market Cap 101.6B USD
Net Margin
-5%
Country US
Market Cap 94.1B EUR
Net Margin
-392%
Country AU
Market Cap 134.4B AUD
Net Margin
18%
Country US
Market Cap 78.5B USD
Net Margin
34%
Country US
Market Cap 39.3B EUR
Net Margin
-33%
Country NL
Market Cap 36B EUR
Net Margin
-14%
No Stocks Found

VistaGen Therapeutics Inc
Glance View

Market Cap
67.4m USD
Industry
Biotechnology

VistaGen Therapeutics, Inc. is a clinical-stage biopharmaceutical company committed to developing and commercializing new generation medications that go beyond the current standard of care for anxiety, depression, and other central nervous system (CNS) disorders. The company is headquartered in South San Francisco, California and currently employs 31 full-time employees. The company went IPO on 2010-10-18. The firm is engaged in developing and commercializing product candidates for patients with diseases and disorders involving the central nervous system (CNS). The firm's pipeline includes PH94B, a neuroactive nasal spray with potential to treat multiple anxiety disorders that is preparing for Phase III clinical trial for social anxiety disorder (SAD), PH10, a neuroactive nasal spray that is planning for Phase 2b development as a stand-alone treatment for depressive disorder (MDD), and AV-101 which the Company is developing for the treatment of depressive disorder (MDD), suicidal ideation, neuropathic pain, levodopa-induced dyskinesia (LID) and epilepsy. In addition, the Company has developed a human pluripotent stem cell (hPSC) technology platform, CardioSafe 3D, to predict potential heart toxicity of new chemical entities (NCEs).

VTGN Intrinsic Value
1.37 USD
Overvaluation 45%
Intrinsic Value
Price
V

See Also

Discover More
What is Net Margin?

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
-4 518.1%
=
Net Income
-39.6m
/
Revenue
875.7k
What is the Net Margin of VistaGen Therapeutics Inc?

Based on VistaGen Therapeutics Inc's most recent financial statements, the company has Net Margin of -4 518.1%.